Prostaglandin D 2 (PGD 2 ), a major cyclooxygenase product in a variety of tissues, readily undergoes dehydration to yield the cyclopentenone-type PGs of the J 2 -series, such as 15-deoxy-∆ 12,14 -PGJ 2 (15d-PGJ 2 ), that have been suggested to exert anti-inflammatory effects in vivo. Meanwhile, the mechanism of these effects is not well understood and the natural site and the extent of its production in vivo remain unclear. In the present study, we raised a monoclonal antibody specific to 15d-PGJ 2 and determined its production in inflammationrelated events. The monoclonal antibody (mAb11G2) was raised against the 15d-PGJ 2 -keyhole limpet hemocyanin conjugate and was found to recognize free 15d-PGJ 2 specifically.
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metabolites are produced at a number of sites and may reach functionally significant levels in inflammation and its related disorders. In the present study, we raised a monoclonal antibody specific to 15d-PGJ 2 and determine its endogenous production in human atherosclerotic lesions. Moreover, we investigated the intracellular and extracellular production of 15d-PGJ 2 in the activated RAW264.7 macrophages in vitro, and established a novel mechanism of transformation of PGD 2 into the cyclopentenone-type PGJ 2 derivatives, in which PGD 2 is converted to 15d-PGJ 2 via an albumin-independent mechanism.
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Immunoblot Analysis. A gel was transblotted onto a nitrocellulose membrane, incubated with Block Ace (40 mg/ml) for blocking, washed, and treated with anti-COX-2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA). This procedure was followed by the addition of horseradish peroxidase conjugated to a goat anti-mouse IgG F(ab') 2 ELISA Analysis of Extracellular PGD 2 and 15d-PGJ 2 . Extracellular PGD 2 and 15d-PGJ 2 levels were determined in the culture medium of RAW264.7 macrophages activated with LPS. At the end of the incubation period, the medium was collected and stored at -80 °C.
For determination of PGD 2 , a solid phase enzyme immunoassay (Cayman Chemical) was performed as suggested by the manufacturer, and the PGD 2 level was determined using a standard curve and a linear log-logit transformation. For determination of 15d-PGJ 2 in the cell culture medium, the medium (5 ml) was extracted immediately with 3 x 5 ml of ethyl actetate, and the solvent was evaporated under nitrogen. The residue was reconstituted in 200 µl of 7 µl aliquot of the competitor/antibody mixture was added to each well and incubated for 2 h at 37 O C. After discarding the supernatants and washing three times with PBS/Tween, the second antibody was added, and the enzyme-linked antibody bound to the well was revealed as previously described. The 15d-PGJ 2 levels in the medium were determined using a standard curve and a linear log-logit transformation. For determination of 15d-PGJ 2 upon in vitro incubation of PGD 2 in cell-free medium or PBS, an aliquot (200 µl) of the reaction mixtures was directly subjected to the competitive ELISA assay. and cut into 6-mm-thick sections by a cryostat. The sections were rehydrated in distilled water, quenched with 3% hydrogen peroxide for 15 min at 4°C, rinsed in PBS, and pretreated with 3% nonimmune serum followed by blocking endogenous avidin/biotin activity using a kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's instructions.
The sections were then incubated overnight at 4°C with the primary antibodies.
Immunoreaction was visualized by the avidin-biotin-immunoperoxidase complex method using the appropriate Vectastain ABC kit (Vector). Immunostained sections were counterstained with hematoxylin. Sections from which the primary antibodies were omitted served as negative reaction controls. 
Separation of PGD

RESULTS
Monoclonal Antibody Specific to 15d-PGJ 2 . 15d-PGJ 2 is believed to be physiologically formed through the non-enzymatic conversion of PGD 2 but has never been definitively proven to exist in vivo. In view of its biological significance, it is critical to provide evidence that 15d-PGJ 2 is endogenously produced in vivo. To this end, we produced a monoclonal antibody directed to 15d-PGJ 2 . The antibody was raised against the 15d-PGJ 2 -KLH conjugate, which was prepared from the reaction of KLH with 15d-PGJ 2 in the presence of EDC and sulfo-NHS ( Fig. 2A) . During the preparation of the monoclonal antibodies, hybridomas were selected on the basis of the ability of their antibodies to bind to the 15d-PGJ 2 -BSA conjugate. After repeated screening, three clones were obtained. Among them, the antibody produced by the clone 11G2 most strongly recognized the 15d-PGJ 2 -BSA conjugate but did not recognize the native BSA (Fig. 2B) . The antibody was then tested for immunoreactivity with PGs. As shown in Fig. 2C (Fig. 4C) . These results were consistent with the in vivo observations that 15d-PGJ 2 was detected intracellularly in the macrophage-derived foam cells in atherosclerotic lesions (Fig. 3 ). Taken these in vivo and in vitro data together, it is evident that the production of 15d-PGJ 2 , is highly accelerated in the cells during inflammatory processes.
Extracellular Production of 15d-PGJ 2 in the Activated RAW264.7 Macrophages.
PGs are synthesized in a broad range of tissue types and serve not only as autocrine but also as paracrine mediators to signal changes within the immediate environment. Hortelano et al. (17) have also suggested that 15d-PGJ 2 may contribute to the resolution of inflammation as a paracrine factor. The extracellular production of 15d-PGJ 2 in the activated macrophages was indeed suggested by the observation that the culture medium of macrophages treated with LPS exerted an excitotoxic effect on neurons (data not shown). To examine whether 15d-PGJ 2 is extracellularly produced during inflammation, the levels of 15d-PGJ 2 in the culture medium of the activated macrophages were measured by a competitive ELISA assay. As shown in Fig. 5A, the calibration range (0.1 -10 nmol) of the standard curve for 15d-PGJ 2 was obtained. In parallel with the COX-2 up-regulation, the extracellular levels of PGD 2 in the LPS-stimulated the production of PGD 2 , a significant amount of 15d-PGJ 2 was accumulated in the culture medium ( Fig. 5C ). The levels of these PGs reached maximums after 12 h of incubation and then decreased thereafter. These data proved that 15d-PGJ 2 was produced extracellularly during inflammatory processes.
Extracellular Conversion of PGD 2 to 15d-PGJ 2 in Cell-Free Medium and in
Phosphate-buffered Saline. Because PGD 2 is known to be converted sequentially to the J 2 derivatives of PGs in vitro ( Serum albumin has been identified as the plasma protein which can catalyze the in vitro transformation of PGD 2 into the J 2 derivatives of PGs in aqueous buffer (7) . Accordingly, to examine whether serum albumin contained in the medium functioned as a catalyst in the conversion of PGD 2 to 15d-PGJ 2 , 1 mM PGD 2 was incubated in PBS containing 10 mg/ml of human serum albumin. As expected, PGD 2 was similarly converted to 15d-PGJ 2 in PBS containing serum albumin (Fig. 6B ). However, to our surprise, the conversion was dramatically accelerated in the absence of albumin. These data suggest that serum albumin may be rather inhibitory toward the production of 15d-PGJ 2 from PGD 2 .
A Novel PGD 2 Metabolic Pathway. The data ( Fig. 6B ) contradict the mechanism of PGD 2 metabolism ( Fig. 1 ), in which PGD 2 is sequentially converted to PGJ 2 , ∆ 12 -PGJ 2 , and 15d-PGJ 2 and the route of conversion leading from PGJ 2 to ∆ 12 -PGJ 2 is catalyzed by serum albumin, therefore suggesting the presence of an albumin-independent mechanism for production of 15d-PGJ 2 . To establish a mechanism of transformation of PGD 2 into the cyclopentenone-type PGJ 2 derivatives, we developed a chiral HPLC method for separation of 12 PGD 2 metabolites and investigated the conventional PGD 2 metabolic pathway in detail. When PGD 2 (1 mM) was incubated in PBS for 24 h, three products (a, b, and c) were mainly detected (Fig. 7A) . Over the course of the 24 h period of incubation, no additional abundant products were formed and there were only minor changes in the product pattern (data not shown). The UV spectra of these products were almost indistinguishable. Based on the identical retention time and co-chromatography with authentic PGs, the products a, b, and c were suggested to be PGJ 2 , 15d-PGD 2 , 15d-PGJ 2 , respectively. The identification of the products was finally done by LC-MS analysis of the products, which showed molecular ion peaks at m/z 316. Serum albumin has been previously identified as the endogenous catalyst of PGD 2 metabolism (7-9). In addition, these workers have identified ∆ 12 -PGJ 2 as the major product in the albumin-catalyzed PGD 2 metabolism. Hence, to characterize the albumin-dependent PGD 2 metabolic pathway, PGD 2 was incubated in PBS containing human serum albumin (10 mg/ml) at 37 O C, and the products were analyzed by chiral-phase HPLC. As shown in Fig. 8A (upper chromatogram), incubation of PGD 2 with human serum albumin yielded, not only the same products (15d-PGD 2 , PGJ 2 , and 15d-PGJ 2 ) as those detected in the spontaneous conversion of PGD 2 in albumin-free solution (Fig. 7A ), but also a major product which cochromatographed on HPLC with ∆molecular ion (M) + peak at m/z 334.8, which coincided with the theoretical molecular weight of ∆ 12 -PGJ 2 . Thus, the product was determined to be ∆ 12 -PGJ 2 . It was observed that PGJ 2 was converted to both 15d-PGJ 2 and ∆ 12 -PGJ 2 in the presence of human serum albumin (Fig. 8A,   middle) . Moreover, no further conversion of ∆ 12 -PGJ 2 was observed (Fig. 8A, bottom) ,
indicating that ∆ 12 -PGJ 2 represents one of the terminal product of PGD 2 metabolism.
Isomerization of PGJ 2 to ∆ 12 -PGJ 2 was dependent on the incubation time and the concentration of human serum albumin: when human serum albumin was present in excess, PGJ 2 was almost stoichiometrically converted to ∆ 12 -PGJ 2 (Fig. 8B) . Boiling of serum albumin markedly decreased the formation of ∆ 12 -PGJ 2 from PGJ 2 but did not affect the formation of 15d-PGJ 2 ( Fig. 8C) , suggesting that ∆ 12 -PGJ 2 is formed by the enzymatic action of albumin while 15d-PGJ 2 is a nonenzymatically formed product.
Taken together, these data suggest that PGD 2 is sequentially converted to PGJ 2 and 15d-PGJ 2 in an albumin-independent manner and serum albumin is involved only in the process leading from PGJ 2 to ∆ 12 -PGJ 2 (Fig. 9 ).
DISCUSSION
Immunochemical detection is a powerful tool that can be used to evaluate the presence of a desired target and its subcellular localization. The major advantages of this technique over other biochemical approaches are the evaluation of small numbers of cells or archival tissues that may otherwise not be subject to analysis. In this study, we obtained a murine monoclonal antibody, mAb11G2, that clearly distinguished the 15d-PGJ 2 -protein conjugate from the native protein. Characterization of the antibody revealed that the monoclonal antibody was directed almost exclusively against free 15d-PGJ 2 (Fig. 2) . It was expected that mAb11G2 would be useful in assessing the endogenous production of 15d-PGJ 2 in response to inflammatory stimuli. In vivo detection of 15d-PGJ 2 using mAb11G2 was first attempted in the tissue samples from the patients with atherosclerosis. Atherosclerosis is considered to be a form of chronic inflammation resulting from interaction between modified lipoproteins, monocyte-derived macrophages, T cells, and the normal cellular elements of the arterial wall.
This inflammatory process can ultimately lead to the development of complex lesions, or plaques, that protrude into the arterial lumen. In the present study, we confirmed that atheromatous lesions indeed contained high levels of COX-2, colocalizing mainly with foamy macrophages (Fig. 3C ). In addition, 15d-PGJ 2 was also found to localize predominantly with the lesional macrophages (Fig. 3D ). These observations raise the possibility that 15d-PGJ 2 may play a role in the pathogenesis of inflammation-related disorders, such as atherosclerosis.
Activation of the host immune system by Gram-negative bacteria can be reproduced in vitro by incubation of cells with LPS and pro-inflammatory cytokines. Macrophages participate actively in the onset of inflammation and immune system activation by releasing cytokines that amplify the initial inflammatory stimulation, bioactive lipids (e.g., PGs and leukotrienes), reactive oxygen species and reactive nitrogen species that exert cytotoxic effects against pathogens and tumor cells (22) (23) (24) (25) . As result of activation, macrophages express pro-inflammatory enzymes, such as COX-2, nitric oxide synthase-2, and matrix metalloproteinases (25) and produce an array of prostanoids, including PGE 2 and thromboxane A 2 (26) , considered the more atherogenic eicosanoids. In the present study, we provided evidence that the production of 15d-PGJ 2 was augmented in the activated RAW264.7 macrophages with LPS in vitro (Fig. 4) . These data coincided with the observation that the 15d-PGJ 2 synthesis was predominantly enhanced in the macrophagederived foam cells in vivo (Fig. 3) . It is suggested that the enhanced production of 15d-PGJ 2 in the activated macrophages may represent an inflammatory response, which contributes to negative regulation of inflammation. Recent studies have shown that 15d-PGJ 2 is a highaffinity ligand for peroxisome proliferator-activated receptor γ (PPARγ) (27, 28) . 15d-PGJ 2 represses several genes in activated macrophages, including the inducible nitric oxide synthase and tumor necrosis factor α genes, and this repression is suggested to be at least partly dependent on PPARγ expression (10, 11, 29) . The anti-inflammatory effect of 15d-PGJ 2 has also been deduced from models of carrageenin-induced inflammation in which a twophase PG release has been described after expression of COX-2: PGE 2 synthesis predominates during the early inflammatory step, whereas 15d-PGJ 2 substitutes PGE 2 formation at the end of the process, coincident with the accumulation of macrophages (30, 31) .
Therefore, the physiopathological relevance of the enhanced synthesis of 15d-PGJ 2 in activated macrophages may represent a mechanism in which 15d-PGJ 2 functions as a feedback regulator of the inflammatory reponses (31).
On the other hand, recent studies have shown that 15d-PGJ 2 directly inhibits the NF-κB-dependent gene expression through covalent modifications of critical cysteine residues in IκB kinase and the DNA-binding domains of NF-κB subunits (12, 13) , leading to the PPARγ-independent resolution of inflammation. Several previous observations have also indicated that PGD 2 and its J-ring metabolites might exert effects through interactions with intracellular proteins: (i) Narumiya et al. (32) (34, 35) .
Cyclopentenone PGs have also been viewed as important factors in the resolution of the inflammatory process through the potentiation of cell death. The recent study shows that 15d-PGJ 2 plays a role in the resolution of inflammation by inducing apoptosis of activated macrophages (17) . In addition, the observations that the J 2 series of the PGs represent the most potent inducers of intracellular oxidative stress and that the production of reactive oxygen species in the cells is closely associated with the excitotoxic effect of the PGs (16) raises the possibility that the production of cyclopentenone PGs during inflammation may be causally involved in the pathophysiological effects associated with degenerative cell loss.
Indeed, we have detected the 15d-PGJ 2 immunoreactivity in the motor neurons in spinal cords from sporadic amyotrophic lateral sclerosis patients (Shibata, T., Kondo, M., Shibata, N., Kobayashi, M., Osawa, T., & Uchida, K., unpublished observation). Future studies are needed to determine whether and how enhanced 15d-PGJ 2 production functionally affects cell death during inflammatory processes and the net effect in vivo of the interplay between the anti-and pro-inflammatory products of COX in human diseases.
The accumulation of significant amounts of 15d-PGJ 2 was observed in the cell culture medium of activated macrophages (Fig. 5) , suggesting the involvement of mechanisms by which (i) 15d-PGJ 2 is produced intracellularly followed by excretion to the medium and/or
(ii) 15d-PGJ 2 is produced in the medium through the nonenzymatic conversion of PGD 2 . The latter possibility was attested to by the observations that the in vitro incubation of PGD 2 in the cell-free medium resulted in increased 15d-PGJ 2 immunoreactivity (Fig. 6A) . The data suggested that 15d-PGJ 2 could be produced extracellularly via nonenzymatic conversion of PGD 2 and may function as an autocrine and paracrine factor during inflammatory processes (Fig. 10) . The in vitro synthesis of 15d-PGJ 2 was first reported by Fitzpatrick and Wynalda (7).
These authors have shown that human serum albumin catalyzes the in vitro transformation of PGD 2 into three dehydration products, such as ∆ 12 -PGJ 2 , 15d-PGD 2 , and 15d-PGJ 2 . The present study also confirmed the production of 15d-PGJ 2 upon incubation of PGD 2 with serum albumin (Fig. 6A) . However, it is striking to note that the in vitro conversion of PGD 2 to 15d-PGJ 2 was further accelerated in the absence of serum albumin (Fig. 6B) . In other words, serum albumin was highly inhibitory toward the production of 15d-PGJ 2 (Fig. 9) . The data contradict the mechanism of formation of PGJ 2 derivatives (Fig. 1) be initially converted to the dehydration products, PGJ 2 and 15d-PGD 2 ( Fig. 9) . It is suggested that the ketone group of PGD 2 at C 11 facilitates the β-elimination of hydroxyl group at C 9 to form PGJ 2 , whereas a proton at C 12 that is simultaneously allylic and α to the C 11 carbonyl facilitates isomerization of the β,γ-unsaturated enone to a more stable α,β-unsaturated enone followed by dehydration to form 15d-PGD 2 . These initial dehydration reactions proceed independently of serum albumin. The observations that (i) incubation of PGD 2 without serum albumin generated 15d-PGD 2 , PGJ 2 , and 15d-PGJ 2 , but not ∆ 12 -PGJ 2 , (Fig. 7A ) and (ii) PGJ 2 was stoichiometrically converted to 15d-PGJ 2 without generating ∆ 12 -PGJ 2 ( Fig. 7B ) indicate that PGJ 2 is directly converted to 15d-PGJ 2 . Therefore, it appears that PGD 2 is sequentially converted to PGJ 2 and 15d-PGJ 2 in an albumin-independent manner (Fig. 9) . It is likely that formation of an α,β-unsaturated ketone within the cyclopentenone ring facilitate ∆ 12 isomerization followed by dehydration of the C 15 hydroxyl. In the presence of serum albumin, ∆ 12 -PGJ 2 , in addition to 15d-PGD 2 , PGJ 2 , and 15d-PGJ 2 , was newly detected (Fig. 8A) . Serum albumin catalyzed the stoichiometric conversion of PGJ 2 to ∆ 12 -PGJ 2 (Fig. 8A) , which was significantly inhibited by the addition of linoleic acid, a ligand of albumin (data not shown).
In addition, boiling of serum albumin markedly decreased the formation of ∆ 12 -PGJ 2 from PGJ 2 but did not affect the formation of 15d-PGJ 2 (Fig. 8C) , suggesting that ∆ 12 -PGJ 2 is formed by the enzymatic action of albumin. These data suggest that serum albumin is involved only in the process leading from PGJ 2 to ∆ 12 -PGJ 2 (Fig. 9 ).
In summary, we obtained a new murine monoclonal antibody, mAb11G2, that clearly 
